Healthcare & Biotech

San Clemente, Calif. – October 01, 2026 -- Angelalign Technology Inc. (6699.HK) has launched Pressure Points in the European market, a feature that replaces its existing Torque Ridges and delivers a 25% increase in tooth surface contact in its single pressure point configuration.

Angelalign replaces hand-made dimples with a digitally scalable force-control feature

Pressure Points is engineered to apply force at or near the center of the contact point, a departure from the hand-made dimples orthodontists have long used to correct torque and rotation. The company states the simplified dimple shape improves predictability of force application compared with current methods.

Rochester, N.Y. – October 01, 2026 -- Multifocal contact lenses ranked as the fourth most selected anti-aging product category among U.S. consumers aged 38 and older, tying with fitness memberships and aesthetic dental care and outranking cosmetic procedures, according to new CooperVision research.

Survey of 752 U.S. adults exposes a wide awareness gap in presbyopia care

The report, "Unmet Opportunities: Multifocal Contact Lenses and the Anti-Aging Movement (U.S.)," surveyed 752 American adults aged 38 and up, combining the findings with market data on healthy-aging attitudes. Despite ranking high among 10 anti-aging categories once consumers were introduced to the product, more than half of respondents reported little to no familiarity with multifocal contact lenses or did not recognize the term.

Chicago – October 01, 2026 -- Ziegler, a specialty investment bank, has closed a $32,453,000 Series 2026 financing for Lourdes Senior Community, a single-site not-for-profit senior living provider in Waterford, Michigan.

Bond structure splits refunding and new construction debt

The financing comprises $14,453,000 in Series 2026A Refunding Revenue Bonds and $18,000,000 in Series 2026B Bank Draw Down Bonds. Proceeds will refinance Lourdes' outstanding Series 2019 Bonds and fund construction of a new 60-unit independent living building.

WesBanco takes direct placement with full interest-rate swap

The Series 2026 Bonds were structured as a tax-exempt direct placement with WesBanco, including a 100% swap. The deal carries a 10-year bank credit commitment period through September 1, 2026, with final maturity set for September 1, 2046. Ziegler served as both placement agent and swap advisor on the transaction.

Westminster, Colo. – October 01, 2026 -- The Centers for Medicare & Medicaid Services has granted New Technology Add-On Payment status to Cerapedics Inc.'s PearlMatrix P-15 Peptide Enhanced Bone Graft, enabling hospitals to recoup up to 65% of the additional cost tied to the device starting October 1, 2026.

CMS approves alternative NTAP pathway tied to FDA Breakthrough Device status

PearlMatrix, a Class III drug-device combination product for skeletally mature patients with degenerative disc disease in the lumbar spine, received NTAP designation under CMS' alternative pathway, which recognizes products holding U.S. FDA Breakthrough Device designation. The reimbursement applies to eligible Medicare beneficiaries treated as inpatients at hospitals paid under the Medicare Inpatient Prospective Payment System.

Danbury, Conn. – October 01, 2026 -- 108 BioCapital is leading a $4 million investment in SedMed, Inc., a medical device maker whose non-electric toilet lift is already used across more than 40 hospital systems.

Funding targets commercial expansion and hospital studies

The capital will accelerate SedMed's commercial growth, expand distribution and channel partnerships, advance its intellectual property portfolio, and fund additional hospital-based studies, the company said. SedMed's flagship product attaches to most standard toilets and provides adjustable sit-to-stand assistance without electricity, batteries or bathroom remodeling, targeting older adults and individuals with mobility limitations.

Novato, Calif. – October 01, 2026 -- Only about 6.9 million of the estimated tens of millions of Americans with atopic dermatitis (AD) had a documented diagnosis in 2023, roughly one in five of those believed to be affected, according to a new CDC-funded report from the National Eczema Association (NEA).

The State of Atopic Dermatitis Indicator Report, conducted by Milliman and released with 51 state-level briefs covering all 50 states and Washington, D.C., establishes the first national baseline on AD diagnosis, treatment and specialist access. It anchors the four-year State of AD initiative and NEA's October Eczema Awareness Month campaign.

Boston – October 01, 2026 -- Blue Cross Blue Shield of Massachusetts has rolled out 100 pink-wrapped Bluebikes across its Greater Boston bike-share network, pledging $1 per ride up to $10,000 for Breast Cancer Awareness Month, with Lyft matching an additional $10,000 once that threshold is hit.

Blue Cross caps donation at $10,000, triggering a matching Lyft commitment

The fleet, split evenly between 50 classic bikes and 50 ebikes, will circulate through the Bluebikes system from October 1 to October 31. Riders need no code or sign-up; any ride on the limited-edition bikes counts toward the donation pool benefiting Ellie Fund, a Needham, Massachusetts-based nonprofit serving breast cancer patients statewide.

Duluth, Ga. – October 01, 2026 -- Codoxo has been named to the second edition of TIME's World's Top HealthTech Companies 2026 list, a ranking produced with Statista Inc. that evaluated thousands of health-tech firms before selecting the top 500.

TIME and Statista screened companies on financial performance, reputation and online engagement

The list was announced on September 17, 2026, and is published on Time.com. Companies were assessed using three primary data sources: Financial Performance Metrics, Reputation Analysis, and Online Engagement.

Palo Alto, Calif. – October 01, 2026 -- TurnCare, Inc. reported a 36.2% reduction in total hospital-acquired pressure injuries (HAPIs) among ECMO patients following implementation of its GuardianTM System, according to new clinical data presented at the 37th Annual Extracorporeal Life Support Organization (ELSO) 2026 Conference in Nashville, Tennessee.

Single-center study tracks outcomes across 2,707 ECMO days

The retrospective pre- and post-cohort analysis, conducted at M Health Fairview University of Minnesota Medical Center, compared a baseline group of 317 ECMO patients (327 runs, 2,112 ECMO days) against a Guardian-treated cohort of 92 patients (97 runs, 595 ECMO days). Chris Linke, MHI, RN, CSSMBB, presented the findings.

Dublin – October 01, 2026 -- Neuromod Devices has appointed Joe Ghiz as Chief Commercial Officer and Shannon Basham as VP of Channel Development, moves aimed at accelerating global commercial expansion of its tinnitus treatment device, Lenire.